Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Temozolomide Effect on MGMT Activity in Gliomas
NCT00424554Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of temozolomide in glioma, sponsored by Merck & Co.. Started Sep 2006; status: completed.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00424554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424554.